Sector News

Pfizer CEO: Trump's wrong on pharma

January 19, 2017
Life sciences

Forget what you’ve heard about pharma in the court of public opinion lately, Pfizer CEO Ian Read says. The “ethical” industry he knows is nothing like notorious ex-CEO Martin Shkreli’s work, and certainly isn’t “getting away with murder” as President-elect Donald Trump claims.

“Most of the problem of reputation is coming from those that I don’t consider part of the ethical pharmaceutical business,” Read said at the World Economic Forum in Davos, Switzerland, calling out Mylan, former Turing Pharma CEO Shkreli and Valeant Pharmaceuticals by name.

Read argued Tuesday that a “terribly complicated and not transparent” healthcare system in the U.S. has led to the public’s distrust in pharma. Elsewhere in the world, such as in Asia or Latin America, trust in drugmakers is much higher, he pointed out.

The problem? Read figures one component is “perception.” He said the “ethical” industry does research, prices responsibly and seeks to recover its R&D costs. Not mincing his words, he said another segment of the pharma business doesn’t do research, and that sector has done a great deal to mar public opinion.

The stance is similar to PhRMA’s back during the Shkreli price-hike episode. Shortly after a now-notorious overnight price hike by Turing Pharma on Daraprim, the industry group sought to distance itself.

Addressing recent remarks by President-elect Donald Trump that pharma is “getting away with murder,” Read said Trump likely “hasn’t been briefed” on the great deal of competition in the industry.

Trump last week said he’ll push for more competitive “bidding” to save billions in healthcare costs, and Monday backed Medicare price negotiation. But Read contends “it’s a very complicated industry,” one with a “huge amount of bidding and extremely aggressive purchasing.”

Since the infamous Turing Pharma Daraprim move, companies including Mylan and Valeant have been subjected to investigations and countless negative headlines over their own price hikes.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

November 21, 2021

Johnson & Johnson to focus on pharmaceuticals

Life sciences

Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.

November 21, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform

Life sciences

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.

November 21, 2021

What are the benefits of the digital health revolution?

Life sciences

Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless

Send this to a friend